About: Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Sector: Healthcare
Industry: Biotechnology
Latest price: $6.82 (+4.28%)
STTK NASDAQ Shattuck Labs Inc
Shattuck Labs Inc share price
STTK price activity
Último preço
$ 6,820
Variação (24h)
0,28 USD (4,28%)
Volume
3.36M
Volume (média 4 sem.)
-
Abertura
$ 6,64
Variação do dia
$ 6,52 - $ 7,42
Fechamento anterior
$ 6,54
Último negócio
30 Sep, 8:16 pm GMT+0
Atrasado
30 Sep, 8:16 pm GMT+0
STTK price performance
Atrasado
30 Sep, 8:16 pm GMT+0
quote.marketSignals